Pasithea Therapeutics Corp. — Company profile
Healthcare · Biotechnology · United States
Last price 0.3696 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.35M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Details
| Name | Pasithea Therapeutics Corp. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2020 |
| Ipo Date | 2021-09-15 |
| Ceo | Tiago Marques |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US70261F2020 |
| Cusip | 70261F202 |
| Cik | 1841330 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Executive Chairman |
| Daniel H. Schneiderman | Chief Financial Officer |
| Dr. Kartik Krishnan M.D., Ph.D. | Chief Medical Officer |
Contact
| Address | 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139, United States |
| Phone | 786 977 3380 |
| Website | https://www.pasithea.com |